ArticleEuropean journal of nuclear medicine and molecular imaging2026
CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson's disease.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo investigate the relationships among CSF proteomic pathway alterations, dopamine transporter single-photon emission computed tomography (DAT-SPECT)-derived dopamine transporter uptake measures, and cognitive vulnerability, longitudinal cognitive decline, and incident mild cognitive impairment (MCI) in early PD.
methodsWe analyzed data from the Parkinson's Progression Markers Initiative, integrating CSF proteomics, DAT uptake measures, and longitudinal cognitive assessments. Cross-sectional analyses included 318 PD patients and 152 healthy controls with baseline clinical, DAT uptake, and CSF proteomic data. Linear mixed-effects models were used to evaluate 0-5-year cognitive trajectories in 306 PD patients, and Kaplan-Meier and Cox analyses assessed incident MCI in 255 cognitively normal PD patients at baseline.
resultsPD patients showed widespread reductions in DAT uptake across the putamen, caudate, and striatum. A total of 233 CSF proteins were differentially expressed in PD, with enrichment in neuronal development, synaptic signaling, axon guidance, Wnt signaling, glutamatergic synapse, and complement/coagulation pathways. Within PD, neural CSF pathway scores were associated with bilateral caudate DAT uptake and HVLT discrimination performance. Lower baseline bilateral caudate and striatal DAT uptake predicted less favorable longitudinal cognitive trajectories across multiple domains, while CSF pathway scores were associated with domain-specific cognitive changes. In survival analyses, low baseline bilateral caudate DAT uptake was associated with increased risk of incident MCI.
conclusionsThese findings suggest that caudate dopaminergic dysfunction may serve as a clinically relevant imaging marker of cognitive vulnerability in early PD, whereas CSF proteomic pathway alterations provide molecular context for synaptic-axonal and immune-coagulation changes associated with cognitive vulnerability and selected cognitive trajectories.
Indexed as
Identifiers
42472725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.